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Supplementary Table S1  
 
Comparison of glycosylation data (in bold) with findings of earlier studies (in italics) 
 
 








         
 Rhophylac    84      80   12 
  25 Rhophylac    81      82     6 
 BRAD3lab-B   29   69   11   35   51   
109 BRAD3lab-B   15   87     2   21   77   
  59 BRAD3lab-B       2     
 BRAD3clin-B   32   61   16   39   41    62 
109 BRAD3clin-B   26   59   11   59   30    51 
 mBRAD3-B   28       79   64 
Dalton mBRAD3-B   20       high   80 
 BRAD5lab-B       2     
  59 BRAD5lab-B       4     
 BRAD5clin-B   34   64   12   42   43    66 
109 BRAD5clin-B   21   64     8   56   36    34 
 mBRAD5-B   24       90   42 
Dalton mBRAD5-B   20       high   40 
 JAC10-B   46   84     2   24   72   
109 JAC10-B   21   83     5   24   71   
 G12-B   37   84     1   30   69   95  
  49 G12-B   33   56        high  
  49 G108-B   26       high  
  49 Anti-D Ig   30   high     7   23   41   medium  
 rBRAD3-CHO     5   33   49   33   16   74     0 
Dalton rBRAD3-CHO     5   36   45   38   17   high     0 
 rBRAD5-CHO     4   26   56   37     7   91     0 
Dalton rBRAD5-CHO     5   31   49   41   10   high     0 
  82 T125(R297)-CHO    26   56   37     7   81  
 R297-YB2/0     45   29   52   19   34  
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Figure S1.  NP-HPLC chromatograms of released N-glycans from IVIG and anti-Ds
